Sept 18, 2007- Biodel Inc. (Nasdaq: BIOD) announced additional clinical data from its VIAject(TM) program at the 43rd Scientific Sessions of the European Association for the Study of Diabetes (EASD).VIAject(TM) Phase II meal study data was disclosed in an oral presentation at EASD entitled, "Pharmacokinetics and pharmacodynamics of insulin VIAject(TM), lispro and regular human insulin when injected subcutaneously immediately before a meal in patients with Type 1 diabetes."... Biodel's Press release -
